Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 16,135 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorders Clear all

Conditions: Diabetes, Peripheral Neuropathy, Diabetic Foot Ulcer
Interventions: Orpyx Sensory Insole System; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Melanoma
Interventions: hu14.18-IL2; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 15 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Metastatic Breast Cancer
Interventions: BZL101; Drug
Lead sponsor: Bionovo; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Microbiota, Gut Microbiome, Eczema, Microbiome
Interventions: Tailored Recommendations, Consult Call, Educational Email Series; Dietary Supplement · Behavioral
Lead sponsor: Seeding Inc; Industry
Eligibility: 0 Months to 3 Months
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Dermatosis Papulosa Nigra
Interventions: SM-020 gel 1.0%; Drug
Lead sponsor: DermBiont, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Dystrophic Epidermolysis Bullosa
Interventions: PTW-002 10 mg/g gel, Placebo; Drug
Lead sponsor: Phoenicis Therapeutics; Industry
Eligibility: 4 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Stanford, California • Worcester, Massachusetts • Cincinnati, Ohio

Conditions: Breast Cancer
Interventions: Melatonin, Placebo, Questionnaire; Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 40 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cellulitis
Interventions: Not listed
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Hyperhidrosis
Interventions: gravimetric; Other
Lead sponsor: Botanix Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Carpinteria, California

Conditions: Melanoma (Skin)
Interventions: Aspirin 81 mg, Aspirin 325mg; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Metastatic Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Tumor
Interventions: Talazoparib, ASTX727; Drug
Lead sponsor: Kathy Miller; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Indianapolis, Indiana • Winston-Salem, North Carolina

Conditions: Breast Cancer, Colorectal Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer, Acral Lentiginous Melanoma, Head and Neck Squamous Cell Carcinoma, Hepatocellular Carcinoma, Esophageal Squamous Cell Carcinoma, Urothelial Carcinoma, DMMR Colorectal Cancer, MSI-H Colorectal Cancer, Melanoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer
Interventions: ATRC-101, Pembrolizumab, Pegylated liposomal doxorubicin (PLD); Biological · Drug
Lead sponsor: Atreca, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 19
States / cities: Phoenix, Arizona • Tucson, Arizona • Duarte, California + 15 more

Conditions: Breast Cancer, Breast Neoplasms, Cancer of the Breast
Interventions: gemcitabine, docetaxel, capecitabine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 47
States / cities: Glendale, Arizona • Fort Smith, Arkansas • Hot Springs, Arkansas + 44 more

Conditions: Invasive Breast Cancer (Stage I-III), Ductal Carcinoma in Situ, Lobular Carcinoma in Situ, Lobular Carcinoma, Fatigue Related to Cancer Treatment
Interventions: Naltrexone, Sugar Pill; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Sjogren's Syndrome, Autoimmune Diseases, Dry Eyes, Dry Mouth
Interventions: Not listed
Lead sponsor: University of Florida; Other
Eligibility: 9 Years to 21 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions: Autologous cultured dermal and epidermal cells; Biological
Lead sponsor: Aderans Research Institute; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 7
States / cities: Atlanta, Georgia • Chicago, Illinois • Chevy Chase, Maryland + 4 more

Conditions: Rheumatoid Arthritis
Interventions: adalimumab (up to 9 months exposure), methotrexate; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: North Chicago, Illinois

Conditions: Breast Cancer
Interventions: HCQ, Avelumab, Palbociclib; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Chicago, Illinois • Indianapolis, Indiana + 4 more

Conditions: Central Centrifugal Cicatricial Alopecia, Lichen Planopilaris
Interventions: Delgocitinib; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Cancer, Melanoma, Colon Cancer, Differentiated Thyroid Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Metastatic Melanoma, HCC, Metastatic Colon Cancer
Interventions: Solar Simulator; Other
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Healthy Volunteer, Atopic Dermatitis, Hidradenitis Suppurativa
Interventions: KT-474/Placebo, KT-474; Drug
Lead sponsor: Kymera Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 14
States / cities: Phoenix, Arizona • Sun City West, Arizona • Boynton Beach, Florida + 8 more

Conditions: Acne Vulgaris
Interventions: Visonac PDT (MAL PDT), Vehicle cream (placebo), PDT; Drug · Procedure
Lead sponsor: Photocure; Industry
Eligibility: 9 Years to 35 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 8
States / cities: San Diego, California • Chicago, Illinois • Naperville, Illinois + 5 more

Conditions: Breast Fibroadenoma
Interventions: ExAblate 2000; Device
Lead sponsor: InSightec; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 4
States / cities: Boca Raton, Florida • Boston, Massachusetts • Voorhees Township, New Jersey + 1 more

Conditions: Breast Cancer
Interventions: Glutamine, Placebo; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Little Rock, Arkansas

Search by objective public record fields.

Wearable Insoles for Recurrent Diabetic Ulcer Prevention

Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma

A Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer

Flourish: Exploring the Early Infant Gut Microbiome

A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Dermatosis Papulosa Nigra (DPN)

Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene

Melatonin Postoperative Sleep Study in Breast Cancer Patients

Sonographic Features of Cellulitis and Failure of Therapy

A Non-Interventional Study To Assess Sweating

Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma

Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

A Phase III Trial For Patients With Metastatic Breast Cancer

Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer

Examining the Immunological Process of Autoimmune Patients

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002012)

Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis

Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer

Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris

Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors

A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

Efficacy and Safety Study With Visonac Photodynamic Therapy (PDT)

MR Guided Focused Ultrasound Surgery in the Treatment of Breast Fibroadenomas

Glutamine for the Prevention of Radiation Toxicity in Subjects Conserving Therapy